If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

Share Price is delayed by 15 minutes
Get Live Data
95.50    3.00 (3.24%)
Bid:
93.00
Ask:
98.00
Spread: 5.00 (5.376%)
Market Cap: £64.07m
EAH Live PriceLast checked at - London Stock Exchange

Intraday Eco Animal Share Chart

Trading Update

21 Jan 2021 07:00

RNS Number : 3896M
Eco Animal Health Group PLC
21 January 2021
 

ECO Animal Health Group plc

(''ECO" or "the Group")

(AIM: EAH)

 

Trading Update

The Board of ECO Animal Health Group plc is pleased to issue a positive revenue update following the conclusion of its third quarter ended 31 December 2020 and an outlook for the year ending 31 March 2021.

· Group revenue and EBITDA for year ending 31 March 2021 expected to be significantly ahead of market expectations and prior year

· Strength in the Chinese and US markets continues with Group revenue at the end of the third quarter ahead of prior year total revenue

· Limited impact of COVID-19 on the Group to date

In October, the Group provided a revenue update and indicated that the revenue for the first six months was ahead of management expectations and the prior year with strength seen in the Chinese and US markets.

The Board is pleased to confirm that the strength in the Chinese market, supported by the rebuilding of pig herds and the high price for pork, continued through the third quarter and the outlook for the final quarter sales continues these strong trading trends.

Revenue outperformance in certain other markets such as the USA continues to offset weakness in India (and Southeast Asia) such that revenue for the rest of the Group (excluding China) is in line with management expectations for the nine months ended 30 December 2020.

Overall, the revenue outperformance in China, combined with the in-line performance in the rest of the Group, is likely to result in revenue for the year ending 31 March 2021 being significantly ahead of market expectations and the prior year. The current business trends and momentum in China will be monitored closely during 2021.

It is expected that the EBITDA for the year ending 31 March 2021 will also be significantly ahead of market expectations and the prior year.

Audit

As previously announced, the additional difficulties arising from auditing the Group's international operations during the COVID-19 pandemic restrictions and against the backdrop of new auditors and new accounting policies adopted at the time of the most recent interim report resulted in an extension to the reporting deadlines. Progress has been encouraging but there remains work still to do. We are also planning to announce our Interim Results for the six months ended 30 September as soon as possible.

 

Marc Loomes, CEO said:

"We are delighted with the current performance of the Group, particularly in China where the herd restocking and production recovery from African Swine Fever has provided a significant opportunity for the Group. Whilst this has been a particular feature of 2020 it has been underpinned by the resilience of markets like the USA and we look forward with optimism to the announcement of our results for the full year and beyond. We are, as ever, grateful to our staff, our customers and our investors for their continuing forbearance and adaptability to cope with the new ways of working in this most challenging of times."

 

Contacts:

 

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

 

020 8447 6906

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Iqra Amin

 

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

 

About ECO Animal Health

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new product

 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFVFLDIIFIL
Date   Source Headline
9th Oct 20247:00 amRNSIssue of Equity and TVR
1st Oct 20247:00 amRNSTrading Update
27th Sep 20242:21 pmRNSResult of AGM
30th Aug 20243:07 pmRNSDirector/PDMR Shareholding
29th Aug 20247:00 amRNSDeferred Share Option Award to Executive Directors
23rd Aug 20241:18 pmRNSHolding(s) in Company
16th Aug 20247:00 amRNSPosting of the Annual Report and Notice of AGM
12th Aug 20241:30 pmRNSBlock Listing Interim Review
15th Jul 20247:00 amRNSFinal Results
11th Jul 20249:30 amRNSNotice of Results
8th May 20247:00 amRNSRisk Profile Demonstrated for ECOVAXXIN MS
25th Apr 20247:00 amRNSTrading Update on year ended 31 March 2024
8th Apr 20247:00 amRNSHolding(s) in Company
4th Apr 20247:00 amRNSDisposal of non-core product line
22nd Mar 20247:00 amRNSShare Awards to Executive Directors
21st Mar 20249:13 amRNSReplacement: Trading Update
21st Mar 20247:00 amRNSTrading Update
19th Mar 20249:40 amRNSGeneral Meeting Result
27th Feb 20247:00 amRNSPublication of Notice of General Meeting
6th Feb 20247:00 amRNSTrademark Approval for ECOVAXXIN® family in the EU
8th Jan 20247:00 amRNSDisposal of Freehold Properties
5th Jan 20245:05 pmRNSHolding(s) in Company
5th Jan 20245:00 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDeferred Option Awards to Executive Directors
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
27th Nov 202310:00 amRNSInvestor Presentation
27th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
14th Nov 20233:00 pmRNSHolding(s) in Company
9th Nov 20237:00 amRNSCapital Markets Day Events
24th Oct 20237:00 amRNSNew USA and Canada label claim for Aivlosin®
28th Sep 20237:00 amRNSESG Rating
7th Sep 20232:57 pmRNSResult of AGM
10th Aug 20237:00 amRNSNotice of AGM
21st Jul 20234:25 pmRNSPosting of the Annual Report and Accounts
10th Jul 20237:00 amRNSFinal Results for the Year Ended 31 March 2023
5th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jun 20237:00 amRNSIssue of Equity and Total Voting Rights
18th May 20237:00 amRNSHolding(s) in Company
23rd Mar 20237:00 amRNSTrading Update
8th Mar 20237:00 amRNSAnimal Health Innovation Summit
27th Feb 202310:37 amRNSDirector/PDMR Shareholding
24th Feb 20233:19 pmRNSChange of Registered Address
17th Feb 20231:41 pmRNSHolding(s) in Company
13th Feb 20231:55 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 20237:00 amRNSDirector/PDMR Shareholding
20th Jan 202312:14 pmRNSHolding(s) in Company
13th Dec 20223:50 pmRNSDeferred Share Option Awards
30th Nov 20223:01 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.